Table 4

Thromboembolism events in patients during the eculizumab treatment period compared with TE events during the same period of time before eculizumab treatment

TE eventsPilot*TRIUMPHSHEPHERDExtension† (all studies)
Before treatment 
    Patients, no. 11 43 97 195 
    Patient-years, no. 33.0 21.8 93.6 272.1 
    TE events 5 0 21 39 
Eculizumab treatment 
    Patients, no. 11 43 97 195 
    Patient-years, no. 34.2 21.8 96.9 281.0 
    TE events 0.00 0.00 2 3‡ 
TE eventsPilot*TRIUMPHSHEPHERDExtension† (all studies)
Before treatment 
    Patients, no. 11 43 97 195 
    Patient-years, no. 33.0 21.8 93.6 272.1 
    TE events 5 0 21 39 
Eculizumab treatment 
    Patients, no. 11 43 97 195 
    Patient-years, no. 34.2 21.8 96.9 281.0 
    TE events 0.00 0.00 2 3‡ 
*

Includes a 1-year and a 2-year extension study.

†

Includes TRIUMPH placebo-treated patients who transitioned to eculizumab treatment in the phase 3 extension study.

‡

P < .001 for comparisons of eculizumab treatment versus before treatment, signed rank test.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal